| Bioactivity | Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3]. | ||||||||||||
| Invitro | Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2]. | ||||||||||||
| In Vivo | Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2]. Animal Model: | ||||||||||||
| Name | Ablukast | ||||||||||||
| CAS | 96566-25-5 | ||||||||||||
| Formula | C28H34O8 | ||||||||||||
| Molar Mass | 498.56 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. M O'Donnell, et al. Pharmacological profile of Ro 23-3544, a new aerosol active leukotriene receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:512-8. [2]. T Rosenbach, et al. Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis. Br J Dermatol. 1988 Jan;118(1):1-6. [3]. Hans-Michael Eggenweiler, et al. Pyrrolopyrimidines as phosphodiesterase VII inhibitors. US7498334B2. |